Antibody dynamics post-Comirnaty and CoronaVac vaccination in Malaysia

• Main Authors: Cheng Siang, Tan, Vaenessa, Noni, Whilemena Upam, Herman Ulok Melina, Ummi Syafqah, Abdorahman, Joseph Niler, Bimbang, Natasya Marliana, Abdul Malik, Mohammad Esa, Hossen, Md Mizanur, Rahman, Lela, Suut, Asri, Said, Claire, Chen, Bego, Sepop, Morni, Abu Samat, John Chee Ming, Chew, Dewi, Mamora, KongTan, Sian
• Format: Article
• Language: English
• Published: Springer Nature 2022
• Subjects: QR180 Immunology; QR355 Virology; RA0421 Public health. Hygiene. Preventive Medicine
• Online Access: http://ir.unimas.my/id/eprint/39843/4/Antibody%20-%20copy.pdf; http://ir.unimas.my/id/eprint/39843/; https://www.nature.com/srep/; https://doi.org/10.1038/s41598-022-19776-3

Several vaccines have been fast-tracked through clinical trials to mitigate the progression of the SARS‑CoV‑2 pandemic. We analyzed sequential blood samples from 314 recipients of Comirnaty and CoronaVac in East Malaysia for the spike-binding IgG (IgG-S), nucleocapsid-binding IgG (IgG-N), spike-binding IgM (IgM-S) and serum vitamin D (VitD). A subset of samples was analyzed for the neutralizing antibodies (Ig-RBD). Results showed that IgG-S due to Comirnaty was significantly higher than CoronaVac. IgM-S was detected in 80.0% Comirnaty and 69.5% CoronaVac recipients, while IgG-N was detected in 58.1% CoronaVac but not in Comirnaty recipients. All IgG-S-positive vaccines possessed detectable Ig-RBD after the second dose but with a weak to moderate correlation. The serum VitD levels did not influence the antibody magnitude in both vaccines. In essence, SARS-CoV-2 vaccination is an IgG-S-dominant event, Comirnaty was more effective than CoronaVac in mounting IgG-S and Ig-RBD responses, independent of the patient’s VitD level.